Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.57 |
| ▸ | EDNRB | P24530 | 11/20 | 0.57 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | DHPS | P49366 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250216 | 0.91 | EDNRA (0.46) | EDNRAEDNRBDHPS | |
| SCHEMBL5204432 | 0.89 | EDNRA (0.72) | EDNRAEDNRB | |
| SCHEMBL5036458 | 0.82 | EDNRA (0.56) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL5036533 | 0.82 | EDNRA (0.56) | EDNRAEDNRB | |
| SCHEMBL5036528 | 0.82 | EDNRA (0.56) | EDNRAEDNRB | |
| SCHEMBL5039492 | 0.80 | EDNRA (0.55) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL5032727 | 0.80 | EDNRA (0.49) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL5041577 | 0.80 | EDNRA (0.49) | EDNRAEDNRBDHPS | |
| SCHEMBL7254354 | 0.79 | EDNRA (0.63) | EDNRAEDNRB | |
| SCHEMBL6961425 | 0.77 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521631-B2 | N-(6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4 -yl)) 5-isopropyl-pyridine-2-sulfonamide; treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction. | HOFFMANN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |